In this talk, Dave Feldman shares new updates from the Keto-CTA study, comparing results across four independent CT imaging analyses: Cleerly, QAngio, HeartFlow, and semi-quantitative reads by expert readers. He addresses the controversies around LDL-C, ApoB, plaque progression, and regression, revealing why certain datasets conflict, and presents compelling evidence showing verified plaque regression in a subset of participants. (* This talk was provided courtesy of Symposium for Metabolic Health 2025. lowcarbusa.org ) 0:00 – Intro & welcome 0:34 – Disclosures & background on the Keto-CTA study 1:01 – Study design & lean mass hyper-responder criteria 1:45 – CT scans, imaging methods & data acquisition 2:10 – Semi-quantitative vs quantitative analysis explained 3:06 – Timeline of analyses & initial expectations 3:29 – First Cleerly results & early concerns 4:11 – Shared findings: baseline plaque & lack of LDL/ApoB association 5:21 – Paper publication & critics’ reactions...